Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biote (BTMD) Change in Receivables (2021 - 2025)

Biote has reported Change in Receivables over the past 5 years, most recently at -$969000.0 for Q4 2025.

  • Quarterly results put Change in Receivables at -$969000.0 for Q4 2025, down 242.4% from a year ago — trailing twelve months through Dec 2025 was $958000.0 (down 57.74% YoY), and the annual figure for FY2025 was $958000.0, down 57.74%.
  • Change in Receivables for Q4 2025 was -$969000.0 at Biote, down from -$479000.0 in the prior quarter.
  • Over the last five years, Change in Receivables for BTMD hit a ceiling of $1.7 million in Q3 2023 and a floor of -$3.3 million in Q4 2023.
  • Median Change in Receivables over the past 5 years was $448500.0 (2022), compared with a mean of $269222.2.
  • Peak annual rise in Change in Receivables hit 362.99% in 2023, while the deepest fall reached 426.74% in 2023.
  • Biote's Change in Receivables stood at -$671000.0 in 2021, then grew by 5.81% to -$632000.0 in 2022, then plummeted by 426.74% to -$3.3 million in 2023, then skyrocketed by 91.5% to -$283000.0 in 2024, then tumbled by 242.4% to -$969000.0 in 2025.
  • The last three reported values for Change in Receivables were -$969000.0 (Q4 2025), -$479000.0 (Q3 2025), and $1.5 million (Q2 2025) per Business Quant data.